The recent success of CAR therapies suggests that with appropriate safety modifications, we can be cautiously optimistic regarding the potential development of a CSPG4-specific CAR therapy for the treatment of metastatic cancer. This evidence concerns the gene CSPG4 and metastatic malignant neoplasm.